<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061437</url>
  </required_header>
  <id_info>
    <org_study_id>S0701</org_study_id>
    <nct_id>NCT01061437</nct_id>
  </id_info>
  <brief_title>S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)</brief_title>
  <official_title>A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of three different antibiotic
      regimens against Helicobacter pylori (H. pylori).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention of gastric cancer through eradication of H. pylori is one of the most promising
      strategies to reduce the global impact of cancer in the near term. Our long-term goal is to
      prevent gastric cancer by developing and validating an effective, simple, and low-cost
      approach to eradication of H. pylori. Our immediate goal, therefore, is to conduct a
      randomized study to compare the effectiveness of three different drug regimens for H. pylori
      infection. The three study arms are: Standard therapy - 14 day, 3-drug regimen of
      Lansoprazole, amoxicillin and clarithromycin (PACx14); Concomitant therapy - 5 day, 4-drug
      regimen of lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5); Sequential
      therapy - 10 day, 4-drug regimen of lansoprazole, amoxicillin for 5 days, followed by
      lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare 2 experimental antibiotic regimens with a standard 14 day regimen with regard to H. pylori eradication rates at 6 weeks post-randomization.</measure>
    <time_frame>week 6 post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary aims will examine infection rates at 1 year, safety and tolerability of these regimens,&amp; potential differential effects among selected groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1859</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard 14 day, 3-drug regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant Therapy - 5 day, 4-drug regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Therapy - 10 day, 4-drug regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACx14</intervention_name>
    <description>Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Lansoprazole: Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACMx5</intervention_name>
    <description>Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Lansoprazole: Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAx5/PCMx5</intervention_name>
    <description>Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Lansoprazole: Prevacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positive Urea Breath Test documenting H. pylori infection

          -  age 21 - 65 years

          -  no known allergies to study drugs

          -  only member of household participating in study

          -  no known medical conditions (other than H. pylori) that would preclude or require
             antibiotic therapy

          -  patients must be willing to discontinue alcohol use for 15 days (maximum duration of
             treatment plus one day)

          -  patients must be willing to discontinue use of antacids for duration of study
             treatment

          -  patients must not have used proton pump inhibitors (PPI) within 30 days of
             registration. Patients also must be willing to stop using non-study provided PPIs
             until the completion of the 6 week follow-up contact.

          -  patients must not have been treated with antibiotics for H. pylori in the past and
             must not have taken any other antibiotics within 30 days of registration.

          -  patients must be willing to return for 2 follow-up visits: 6 weeks after randomization
             following completion of treatment &amp; 1 year after randomization

          -  patients must be willing to allow submission of blood for assays of serum markers of
             bacterial virulence and host genetic susceptibility and environmental factors and
             provide consent for use of specimens.

        Exclusion Criteria:

          -  current use of anti-retroviral therapy for HIV or AIDS

          -  diagnosed congestive hear failure

          -  renal failure requiring dialysis

          -  diagnosed hepatic failure resulting in hyperbilirubinemia

          -  any current or prior malignancy except: adequately treated basal or squamous cell skin
             cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from
             which the patient has been disease free for 5 years

          -  pregnancy or nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Robert Greenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad del Valle</name>
      <address>
        <city>Cali</city>
        <state>Valle</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Inciensa</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Occidente</name>
      <address>
        <city>Copan</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Public Health</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Technologico de Sonora</name>
      <address>
        <city>Obregon</city>
        <state>Sonora</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Demografia y Salud de la Iglesia Merced</name>
      <address>
        <city>Leon</city>
        <country>Nicaragua</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Honduras</country>
    <country>Mexico</country>
    <country>Nicaragua</country>
  </location_countries>
  <link>
    <url>http://www.swog.org/</url>
    <description>Click here for more information about the study: S0701, &quot;A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori.&quot;</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H. pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

